Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02179749 · ClinicalTrials.gov registry record · Phase 2

Mifepristone Treatment of Alcohol Use Disorder

A Phase 2 study of Alcoholism and Alcohol Abuse, sponsored by The Scripps Research Institute.

Completed
Registry status
Phase 2
Development phase
103
Enrollment target
1
Study location

NCT02179749 is a Phase 2 study of Alcoholism and Alcohol Abuse that has completed, run by The Scripps Research Institute. The registered enrollment target is 103 participants, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02179749, a Phase 2 study of Alcoholism and Alcohol Abuse, has completed, sponsored by The Scripps Research Institute.

COMPLETED
Registry status
Phase 2
Development phase
103 participants
Enrollment target
1
Study location

Study Summary

This is an 8-week, randomized, double-blind, placebo-controlled, 2 arm, parallel groups, study of 1-week of treatment with mifepristone (0, 1200 mg/d) given in conjunction with 8 weeks of manual-guided counseling, and a follow-up visit at Week 12.

Interventions

  • DRUG Placebo
  • DRUG Mifepristone 1200 mg daily
  • BEHAVIORAL Standardized behavioral therapy

Study Locations (1)

California

  • The Scripps Research Institute - La Jolla

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2014-09
Est. Completion 2019-11-06
Phase Phase 2

Sponsor

The Scripps Research Institute

16 total trials

What the Registry Record Tells You About NCT02179749

The ClinicalTrials.gov registry entry for NCT02179749 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (72% lower). The listed sponsor is The Scripps Research Institute, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Alcoholism appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02179749 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02179749 about?

NCT02179749 is a clinical study titled "Mifepristone Treatment of Alcohol Use Disorder". This is an 8-week, randomized, double-blind, placebo-controlled, 2 arm, parallel groups, study of 1-week of treatment with mifepristone (0, 1200 mg/d) given in conjunction with 8 weeks of manual-guided counseling, and a follow-up visit at Week 12.

What is the current status of trial NCT02179749?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2014-09. Estimated completion is 2019-11-06.

What conditions does trial NCT02179749 study?

This clinical trial studies the following conditions: Alcoholism, Alcohol Abuse, Alcohol Dependence, Alcohol Use Disorders.

What interventions are being tested in trial NCT02179749?

The interventions under investigation include: Placebo (DRUG), Mifepristone 1200 mg daily (DRUG), Standardized behavioral therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT02179749?

This trial is sponsored by The Scripps Research Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02179749 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcoholism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.